Changchun Keygen Biological Products Co., Ltd. Report issue

For profit Phase 4
Founded: Changchun China (2003)
Status: Acquired by China National Biotec Group Co., Ltd (2017)

Organization Overview

First Clinical Trial
2013
NCT01817270
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2016

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Chickenpox (Phase 4)

Encephalitis (Phase 4)

Encephalitis, Japanese (Phase 4)

Herpes Zoster (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 3
  • # of Trial APIs: 2